---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-368422"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2021-12-29T23:59:59+00:00"
generated_at: "2026-06-27T21:58:16.914083+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Director Morana Jovan-Embiricos resigns from Cullinan Oncology board effective Dec 31, 2021

## Summary
- Resignation to dedicate more time to role as Managing Partner of F2 Ventures Ltd. and its portfolio companies.
- Decision not due to any disagreement with the Company on operations, policies, or practices.
- Resignation effective December 31, 2021; no replacement announced.

## SEC filing metadata
- accession: 0001193125-21-368422
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2021-12-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000119312521368422/0001193125-21-368422-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000119312521368422/d282038d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-368422
- JSON: https://secwatch.observer/filing/0001193125-21-368422.json
- Plain text: https://secwatch.observer/filing/0001193125-21-368422.txt

## Key facts
- Executive change
  Morana Jovan-Embiricos departed as Director at Cullinan Therapeutics, Inc..
  - Action: resigns as director
  - Role: Director
  source text: On December 27, 2021, Morana Jovan-Embiricos notified the Board of Directors of Cullinan Oncology, Inc. (the “Company”) of her intention to resign as a director effective as of December 31, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789972/000119312521368422/0001193125-21-368422-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.